Internet Pioneer In...
Health Care: Drugs
Compugen Ltd. (CGEN: NASDAQ)
$3.41 -0.12 | -3.40%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.41 |
| 52 Week High | 6.47 |
| 52 Week Low | 3.32 |
| Avg. Daily Vol. (Mil) | 0.12 |
| Beta (3 year) | 2.20 |
| Share Related Items | |
| Mkt Cap (Mil) | 118.35 |
| Shares Out (Mil) | 34.71 |
| Float (Mil) | 32.85 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 12.00 |
| Current Ratio | 12.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 5.57 |
| Price/Cash Flow | -8.50 |
| Per Share Data | |
| Earnings | -0.41 |
| Sales | 0.00 |
| Book Value | 0.61 |
| Cash Flow | -0.40 |
| Business Summary | |
|---|---|
| Compugen, Ltd. engages in drug and diagnostic product candidate discovery and commercialization of such candidates largely through early stage licensing and development agreements. | |
| General Information | |
| 72 Pinchas Rosen Street
Tel Aviv, 69512 |
|
| 1.0 | |
| www.cgen.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 39 | |
| CEO: Anat Cohen Dayag,PhD | |
| Short Interest | |
| Current Month (Mil) | 0.49 |
| Previous Month (Mil) | 0.47 |
| Short Interest Ratio (Days) | 4.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -43.80 |
| Return on Investments | -66.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CGEN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Bargain Biotech Stocks
- Userdesignbydiana Portfolio 1
- Userraveha1 Portfolio 1
- ContributorBiotech Short Squeezes
- UserSUPRATRADE-QUANTUM STARDUST 8
- UserHumelor Portfolio 1
Latest CGEN Headlines from TheStreet
- 7 Stocks Under $10 Soaring Higher 05.24.12 | 12:05 pm
- 5 Bargain Biotech Stocks 01.13.11 | 05:01 pm
- Maguire Properties, Compugen: Midday Volume Plays 05.11.10 | 11:05 am
- eOn Communications, Compugen: Early Volume Plays 03.16.10 | 09:03 am
- Pluristem Therapeutics, Compugen: Early Volume Plays 03.02.10 | 09:03 am
- Array BioPharma, Sterling Financial: Early Volume Plays 02.02.10 | 09:02 am
- Biotech's Movers & Shakers 2009: BioBuzz 01.04.10 | 09:01 am
- Compugen, Flotek: Early Volume Plays 01.04.10 | 07:01 am
- China BAK, Compugen: Early Volume Plays 12.30.09 | 08:12 am
- Compugen, Sinovac: Early Volume Plays 12.28.09 | 08:12 am
Press Releases for CGEN
- Dr. Mary Haak-Frendscho, Chairperson Of Compugen’s US Subsidiary, To Give Keynote Address At China Pharmaceutical R&D Summit - Business Wire 04.23.12 | 07:04 am
- Compugen First Quarter 2012 Conference Call Scheduled For Tuesday, May 1, 2012 At 10:00 AM EST - Business Wire 04.23.12 | 07:04 am
- Compugen Presents Prediction Based Discovery Strategy At “Targets And Strategies For Drug Discovery” Conference - Business Wire 02.27.12 | 07:02 am
- Compugen Cancer Target Results Demonstrate Significant Potential For Cancer Immunotherapy - Business Wire 02.02.12 | 06:02 am
- Compugen To Broaden And Accelerate Monoclonal Antibody Program For Oncology And Immunology - Business Wire 12.20.11 | 10:12 am
- BioLineRx To Develop And Commercialize Novel Peptide Drug Candidates Discovered By Compugen - Business Wire 12.13.11 | 06:12 am
- Compugen Presents Predictive Drug Target Discovery Platform At European Antibody Conference - Business Wire 11.30.11 | 07:11 am
- Www.discoverx.com - Business Wire 11.29.11 | 07:11 am
- Compugen Reports Third Quarter 2011 Financial Results - Business Wire 11.08.11 | 07:11 am
- Compugen's CGEN-15001 Pre-Clinical Data Presented At International Conference On Immune Tolerance - Business Wire 10.25.11 | 07:10 am
Partner Headlines for CGEN
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Compugen: On the Road to Breakthroughs - Seeking Alpha 05.12.10 | 03:05 am
